Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic review
- 30 September 2019
- journal article
- review article
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (6) , 843-853
Abstract
Background: Cyclosporine is a useful immunosuppressive agent for achieving disease control in moderate to severe atopic dermatitis in children and adults. However, it carries the potential for nephrotoxicity. Monitoring of drug levels is performed in other patient groups, such as transplant recipients, but is not commonplace in the management of atopic dermatitis.Objectives: To investigate levels of nephrotoxicity associated with cyclosporine use in atopic dermatitis and assess potential correlation with trough levels of cyclosporine.Methods: An electronic search was conducted on MEDLINE, EMBASE, and Cochrane databases for randomized controlled trials and cohort studies assessing the safety profile of cyclosporine compared to placebo or other atopic dermatitis treatments, in adult and pediatric atopic dermatitis patients from 1966 to May 2019. Studies that did not assess renal toxicity were excluded from analysis.Results: Thirty‐eight trials were included for analysis, excluding 11 that did not assess renal toxicity. Descriptive statistical analysis only was performed, due to the high heterogeneity between study methodologies. Significant renal toxicity was seen in 0%‐9% of pediatric participants. Monitoring of trough cyclosporine levels was performed in only 10 of the studies, and their correlation to toxicity or disease activity was not explored.Conclusion: There is limited evidence in atopic dermatitis regarding trough level monitoring of cyclosporine. Currently, the practice is not commonplace, particularly in pediatrics, and this is reflected in trial methodology. Monitoring may be useful in specific pediatric groups, such as those on multiple concurrent medications, patients with hepatic or renal dysfunction and non‐responders to therapy.Keywords
This publication has 50 references indexed in Scilit:
- Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from EgyptEuropean Journal of Pediatrics, 2012
- Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trialJournal of the American Academy of Dermatology, 2011
- Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's HealthJournal of Investigative Dermatology, 2011
- The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic DermatitisAnnals of Dermatology, 2010
- Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta‐analysisJournal of the European Academy of Dermatology and Venereology, 2007
- A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of lifeJournal of the American Academy of Dermatology, 2000
- Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis*British Journal of Dermatology, 1996
- Cyclosporine in severe childhood atopic dermatitis: A multicenter studyJournal of the American Academy of Dermatology, 1996
- Cyclosporin A in atopic dermatitis: therapeutic resonse is disociated form effects on allergic reactonsBritish Journal of Dermatology, 1991
- Cyclosporine therapy for severe atopic dermatitisJournal of the American Academy of Dermatology, 1989